Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Insite Vision Incorporated v. Sandoz, Inc.
Case Number:
14-1065
Court:
Nature of Suit:
830 Patent Infringement (Fed. Question)
Companies
Sectors & Industries:
-
April 09, 2015
Fed. Circ. Affirms Sandoz Loss In Generic AzaSite Case
The Federal Circuit on Thursday affirmed a lower court's ruling barring Sandoz Inc. from marketing a generic version of the eye infection drug AzaSite, ruling that the company has failed to show that patents owned by Pfizer Inc. and others are invalid as obvious.
-
November 06, 2013
Sandoz Appeals Eye Drug Patent Verdict To Fed. Circ.
Sandoz Inc. asked the Federal Circuit on Tuesday to reverse a federal judge's ruling that the pharmaceutical company violated four patents owned by Pfizer Inc. and InSite Vision Inc. when it tried to bring to market a generic version of AzaSite azithromycin eye drops, used as a bacterial conjunctivitis treatment.